Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19

Oliver J McElvaney\textsuperscript{a,b}, Eoin O’Connor\textsuperscript{b}, Natalie L McEvoy\textsuperscript{c}, Daniel D Fraughan\textsuperscript{b}, Jennifer Clarke\textsuperscript{b,c}, Oisin F McElvaney\textsuperscript{a}, Cedric Gunaratnam\textsuperscript{b}, James O’Rourke\textsuperscript{b}, Gerard F Curley\textsuperscript{b,c}, Noel G McElvaney\textsuperscript{a,b,*}

\textsuperscript{a} Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
\textsuperscript{b} Beaumont Hospital, Dublin, Ireland
\textsuperscript{c} Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

A R T I C L E   I N F O

Article history:
Received 22 August 2020
Revised 16 October 2020
Accepted 16 November 2020
Available online 20 November 2020

Keywords:
Coronavirus
COVID-19
Cystic fibrosis
Alpha-1 antitrypsin
Inflammation
Cytokinemia
Interleukin-1β
Interleukin-6
Neutrophil elastase
Anti-inflammatory

A B S T R A C T

Background: The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation.

Methods: IV AAT was administered at 120 mg/kg/week for 4 consecutive weeks. Levels of interleukin (IL)-1β, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were assessed at regular intervals in plasma, with IL-1β, IL-6, IL-8 and neutrophil elastase (NE) activity measured in airway secretions. Levels were compared to baseline and historic severe exacerbation measurements.

Results: Systemic and airway inflammatory markers were increased compared to both prior exacerbation and baseline levels, in particular IL-6, IL-1β and NE activity. Following each AAT dose, rapid decreases in each inflammatory parameter were observed. These were matched by marked clinical and radiographic improvement.

Conclusions: The results support further investigation of AAT as a COVID-19 therapeutic, and re-exploration of its use in CF.

© 2020 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.

1. Introduction

Coronavirus disease 2019 (COVID-19) is a global threat to health. Those with severe disease typically develop a febrile pro-inflammatory cytokinemia with accelerated progression to acute respiratory distress syndrome (ARDS) [1]. While SARS-CoV-2 infection in cystic fibrosis (CF) has previously been reported [2], the clinical and biochemical course of severe COVID-19 in the context of advanced CF remains incompletely understood.

We present the case of a 43 year old woman with CF who developed COVID-19 while an inpatient, following a ward-level outbreak. A precautionary nasopharyngeal swab obtained while the patient was asymptomatic was negative on a reverse-transcriptase–polymerase-chain-reaction assay. However, several days later following the onset of low-grade pyrexia, increased dyspnea and cough above baseline, a repeat swab was positive for COVID-19.

1.1. Pre-study clinical baseline and phenotype

The patient, who was diagnosed in early childhood, was homozygous for the p.Gly551Asp (previously termed G551D) mutation, and in late 2012 became one of the first Irish people with CF (PWCF) to receive ivacaftor. However, she had established structural airways disease and severely compromised pulmonary function at the time of commencement. Despite sustained improvements in body mass index and decreased exacerbation frequency, she remained chronically infected with Pseudomonas aeruginosa and Stenotrophomonas maltophilia, and an initial stabilization in forced expiratory volume in 1 second (FEV₁) gradually gave way to clinical decline (Fig. 1). Of relevance to COVID-19, Stenotrophomonas degrades the airway epithelial cell tight junction proteins ZO-1 and occludin, a pathogenic mechanism that may facilitate enhanced viral entry [3]. This process is likely mediated via...
The patient demonstrated a progressive decrease in FEV₁ between 2010 and late 2012. Commencement of ivacaftor in late 2012 (green arrow) resulted in initial stabilization of lung function, but was followed by gradual resumption of FEV₁ decline. The IECF that triggered the patient’s 2019 admission to ICU, during which she underwent a tracheostomy, is indicated with a red arrow (for interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Secreted virulence factors including the extracellular serine proteases StmPR1, StmPR2, and StmPR3, and is also blocked by protease inhibition.

A severe exacerbation in September 2019 necessitated an ICU admission for intubation and mechanical ventilation, but she responded well enough to return to the CF ward with a tracheostomy in situ. She was accepted onto the active lung transplant list in late 2019, with an FEV₁ of 0.73 L (26% of the predicted value), and elected to remain in hospital until a donor organ became available.

1.2. Clinical course

The patient experienced a pronounced and rapid deterioration within 2 days of the onset of symptoms; her respiratory rate rose to 48 breaths/min despite maximal bi-level positive airway pressure support via her tracheostomy and supplemental oxygen at 10 L/min. This was accompanied by hypotension, tachycardia and worsening fever.

She was admitted to the ICU for mechanical ventilation; at this point, she met the criteria for diagnosis of severe ARDS, with a PaO₂/Fio₂ of 96 mmHg (Table 1). In addition to a widespread cytokopenia, circulating levels of C-reactive protein and lactate were elevated, as were several other critical illness markers known to be increased in severe COVID-19, such as lactate dehydrogenase, ferritin, procalcitonin and D-dimer. Following her re-admission to ICU on this occasion, the patient was suspended from the active transplant list.

1.3. Airway inflammation at admission to ICU

Bronchoscopy was undertaken upon ICU arrival to relieve mucous plugging and perform bronchoalveolar lavage (BAL). Central to airway inflammation and lung injury in both cystic fibrosis (CF) and ARDS is neutrophil elastase (NE), an omnivorous serine protease released by activated or disintegrating neutrophils [4]. NE activity levels and cytokines in the BAL fluid obtained were compared to levels from BAL fluid collected at a recent routine bronchoscopy performed at the patient’s clinical baseline and BAL fluid obtained during a previous infective exacerbation of CF (IECF, Table 2). Airway NE activity was markedly increased in the ICU sample, as were the levels of interleukin (IL)–1β, IL-6 and the potent neutrophil chemoattractant IL-8 (Table 2). Plasma concentrations of these cytokines, along with levels of soluble tumor necro-

![Fig. 1. Lung function over time prior to SARS-CoV-2 infection.](image)

The patient’s FEV₁ from 2010 to 2020 is shown. The green arrow indicates the commencement of ivacaftor in late 2012, resulting in an initial stabilization of lung function, followed by a gradual resumption of FEV₁ decline. The red arrow indicates the IECF that triggered the patient’s admission to the ICU.

Table 1

| Variable                        | Normal value or range |
|---------------------------------|-----------------------|
| Heart rate (beats/minute)       | 108                   |
| Respiratory rate (breaths/minute)| 48                    |
| Blood pressure (mmHg)           | 103/68                |
| Temperature (°C)                | 39.5/103.1            |
| Peripheral oxygen saturation (%)| 91                    |
| Arterial blood gas              |                       |
| PaO₂ (kPa)                      | 7.7                   |
| PaCO₂ (kPa)                     | 6.9                   |
| pH                              | 7.45                  |
| PaO₂/Fio₂ (mmHg)                | 96                    |
| Lactate (mmol/l)                | 1.2                   |
| C-reactive protein (mg/l)       | 372                   |
| White cell count (10⁹/l)        | 5.69                  |
| Neutrophils                     | 4.59                  |
| Lymphocytes                     | 0.87                  |
| Monocytes                       | 0.21                  |
| Eosinophils                     | 0.02                  |
| Hemoglobin (g/dl)               | 9.8                   |
| Alanine aminotransferase (IU/l) | 13                    |
| Aspartate aminotransferase (IU/l)| 36                   |
| Albumin (IU/l)                  | 34                    |
| Urea (mmol/l)                   | 3.2                   |
| Creatinine (µmol/l)             | 36                    |
| Lactate dehydrogenase (U/l)     | 704                   |
| Ferritin (ng/ml)                | 1646                  |
| Fibrinogen (g/l)                | 7.8                   |
| Procalcitonin                   | 0.56                  |
| D-Dimer                         | 3.2                   |
| Alpha-1 antitrypsin (g/l)       | 2.64                  |

| Variable                        | Normal value or range |
|---------------------------------|-----------------------|
| PaO₂ – partial pressure of arterial oxygen. |                       |
| PaCO₂ – partial pressure of arterial oxygen. |                       |
| PaO₂/Fio₂ – ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen. |                       |

AAT is a 52 kDa glycoprotein synthesized primarily in the liver, and the archetypal serine protease inhibitor, acting to protect the airway from NE-mediated damage [6–8]. Of additional relevance to COVID-19, AAT is also a potent immunomodulator, regulating the production and activity of several key pro-inflammatory cytokines, including IL-1β, IL-6, IL-8 and TNF-α [9–14], while preserving the production of IL-10 [14,15]. Plasma-purified AAT (Prolastin) was provided on compassionate grounds by Grifols Pharmaceuticals, Spain. Intravenous (IV) administration was preferred to the aerosol route for two reasons. First, the patient displayed significant systemic inflammation; second, the use of an aerosol-generating device may have introduced a safety hazard by increasing the risk of viral transmission.

1.5. Anti-protease and anti-inflammatory effects observed following administration of IV AAT

A dose of 120 mg/kg was chosen given the half-life of IV AAT, and its successful inhibition of airway NE in AAT-deficient individ-

---

*O.J. McElvaney, E. O’Connor, N.L. McEvoy et al.*
Table 2
Inflammatory cytokines and neutrophil elastase activity levels relative to baseline.

| Inflammatory mediators | Baseline | Most recent severe IECF | COVID-19 |
|-------------------------|----------|--------------------------|----------|
| Blood cytokines (pg/ml) |          |                          |          |
| IL-1β                   | 12.1     | 20.7                     | 141.4    |
| IL-6                    | 63.8     | 97.4                     | 571.3    |
| IL-8                    | 88.3     | 119.9                    | 238.7    |
| sTNFR1                  | 2870.9   | 3615.1                   | 4092.5   |
| Airway cytokines (pg/ml) |         |                          |          |
| IL-1β                   | 202.6    | 299.0                    | 374.6    |
| IL-6                    | 104.7    | 198.4                    | 633.9    |
| IL-8                    | 492.2    | 658.3                    | 788.1    |
| Airway NE activity (nM) |          |                          |          |
|                         | 741.9    | 905.6                    | 1298.8   |

* Also required intensive care unit admission.
† At time of admission to intensive care unit.
‡ Measured in bronchoalveolar lavage fluidIECT – infective exacerbation of cystic fibrosisIL – interleukin TNFR1 – soluble tumor necrosis factor receptor 1.

Fig. 2. Thoracic imaging for the patient over time.
A high-resolution chest CT obtained at the patient’s baseline (Panel A) demonstrated extensive and bilateral varicose bronchiectasis, more pronounced within the right lung and associated with mucus plugging and bronchial wall thickening. In Panel B, chest radiography from the day the patient tested positive for COVID-19 showed bilateral infiltrates. Panel C shows the patient’s chest radiograph on the morning of commencement of AAT therapy. Volume loss in the right hemithorax was associated with a right-sided pleural effusion. Extensive opacification was observed throughout the right lung. Airspace change in the left lung was most confluent at the left upper zone. The chest radiograph shown in Panel D was taken at the conclusion of therapy (day 28) and demonstrated bilateral radiological improvement.

Fig. 3B and C demonstrate increased AAT-NE complexes two days after the initial AAT dose, with this pattern replicated following subsequent doses, (day 9, day 16), confirming that the decrease in NE activity was due to direct inhibition by AAT in the form of a direct binding event.
1.6. Clinical status at one month

IV AAT was well tolerated throughout, with no adverse events attributable to the drug encountered. At one month, following radiographic improvement (Fig. 2D) and return to her airway inflammatory baseline, the patient was successfully liberated from sedation and mechanical ventilation. While she had experienced physical deconditioning with loss of muscle mass, she did not demonstrate clinical evidence of critical care myopathy, and was ambulatory within days. Her tracheostomy remained in situ, both to facilitate suctioning of airway secretions, and in anticipation of a lung transplant following her return to the active list.

2. Discussion

Here we report the first successful administration of IV AAT for severe cytokinemic COVID-19 complicated by ARDS. While the magnitude and nature of the inflammatory response observed differentiated it from a typical IECF, the present case cannot be ascribed solely to COVID-19. Instead, it likely represents the coalescence of two heavily pro-inflammatory conditions. The blended immunophenotype and rapid clinical decline that ensued were unresponsive to conventional ARDS management, prompting the off-label use of plasma-purified AAT as a salvage therapeutic. In addition to a systemic anti-inflammatory effect, airway cytokine concentrations and NE activity decreased in following treatment, and were matched by clinical improvement.

This study is limited in that it involved treatment of one patient only. However, this allowed us to investigate in greater detail than would have otherwise been possible. We were fortunate in that regular airway sampling throughout the treatment period was made possible by the presence of a pre-existing tracheostomy, thereby facilitating the demonstration of a biological response to AAT in the airway. Had we been confined to BAL at less frequent intervals, we would have failed to capture the effects identified here. While it was clinically indicated in this case, conserved tracheostomy tubes may also introduce an element of risk in CF if they are not accompanied by regular physiotherapy, cough training and suctioning protocols, since they can impair the natural cough mechanism.

Although airway NE activity is increased in patients with ARDS, the levels encountered here are more consistent with severe CF lung disease and chronic infection. Similarly, while the blood and airway cytokinemia observed was more in keeping with severe COVID-19, several CF-related factors are likely to have contributed to the patient’s cytokine profile. For example, both macrophages and neutrophils undergo metabolic reprogramming in advanced CF, with increased aerobic glycolysis and inflammatory activation promoting increased production and processing of IL-1β [18,19]. NE induces further release of IL-1 and IL-8 from respiratory epithelial cells [20], with IL-1 in turn upregulating IL-6 in viral illness [21]. This begs the question of whether the novel therapeutic approach taken here is applicable to non-CF patients with severe COVID-19. The answer may be provided by a randomized, multi-center, double-blind, placebo-controlled trial of IV AAT for ARDS secondary to COVID-19 currently underway (EudraCT 2020-001391-15).

The implications of this study for PWCF go beyond COVID-19. In discussions regarding the allocation of resources and ICU support during the COVID-19 pandemic, patients with significant CF lung disease are at risk of being overlooked. Current CF Foundation guidelines state that PWCF with advanced disease should be considered for ICU [22]. However, as concerns regarding ventilator shortages mount, PWCF risk being included in the same triage categories as older and less functional patients suffering from more common chronic pulmonary diseases [23]. Similarly, practice guidelines that are not based on more recent prognostic data [24] may discriminate unfairly against PWCF. The findings may also prompt re-exploration of AAT as an anti-protease and anti-inflammatory CF therapeutic. Prior attempts to reduce airway inflammation using inhaled AAT strategies have provided mixed results [25–27], with the heterogeneity of the CF lung, and differences in mucus rheology between PWCF potentially contributing.
to the variability observed between studies. These potential confounders may not have applied to the same extent in this instance due to the IV route of administration used.

Moreover, previous studies focused primarily on AAT as a maintenance treatment, rather than an IECF therapeutic. The anti-inflammatory effects of AAT, coupled with its protection against C-X-C motif chemokine receptor 1 (CXCR1) cleavage – a protease-driven event that results in impaired phagocytosis of Pseudomonas aeruginosa [28] – would seem to support further investigation of the latter.

As our understanding of the clinical and inflammatory characteristics of severe COVID-19 evolve, so too does our knowledge of the natural history of SARS-CoV-2 infection in CF. Although these data do not necessarily apply to all COVID-positive PWCF, they do identify a potential therapeutic for those who are in extremis. Perhaps most importantly, the outcomes described emphasize the importance of translational research in driving patient-tailored care. In this instance, a personalized approach was facilitated by an understanding of the molecular basis of inflammation and the pathogenesis of multiple conditions in a critically unwell patient. At a time of unprecedented demand on health services, precision medicine remains possible.

Credit author statement

Author contributions: O.J.McE., G.F.C. and N.G.McE. conceptualized the study; O.J.McE., E.O.C., N.L.McE., D.F. J.C. O.F.McE., C.G., J.O.R., G.F.C. and N.G.McE. collected clinical data, attended to the patient and administered treatment; O.J.McE., E.O.C., N.L.McE., D.F., O.F.McE., C.G. and J.O.R. collected and processed samples; O.J.McE., N.L.McE. and O.F.McE. designed and performed experiments; O.J.McE., E.O.C. and N.L.McE. co-wrote the manuscript; All authors edited the manuscript.

Sources of support

O.J.McE. received support from the Elaine Galwey Memorial Research Bursary and the American Thoracic Society in the form of an ATS International Trainee Scholarship award and an ATS abstract scholarship award.

Declaration of Competing Interest

N.G.McE. has previously been an investigator in trials for CSL Behring, Grifols and Vertex. He has sat on advisory boards for CSL Behring, Grifols, Chiesi and Shire. The remaining authors have no conflicts of interest to declare.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcf.2020.11.012.

References

[1] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020.
[2] Coogiff R, Ahrens S, Bell SC, Brownlee K, Burgett PR, Byrnes C, et al. A multinational report to characterize SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros 2020;19(3):355–8.
[3] Molloy K, Cagney G, Dillon ET, Wynne K, Greene CM, McElvany NC. Impaired airway epithelial barrier integrity in response to stenotrophomonas maltophilia proteases, novel insights using cystic fibrosis bronchial epithelial cell secretomics. Front Immunol. 2020;11:198.
[4] Cantin AM, Hartli D, Konstan MW, ChinellI F. Inflammation in cystic fibrosis lung disease: pathology and therapy. J Cyst Fibros 2015;14(4):419–30.
[5] McElvany OJ, McEvoy N, McElvany OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med 2020.
[6] Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994;150(5 Pt 2):514–17.
[7] Wewers MD, Casaloro MA, Sellers SE, Swayne SC, McPhaul KM, Wittert JT, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316(17):1055–62.
[8] Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PZ subjects. J Clin Invest. 1981;68(5):1158–65.
[9] Jonigk D, Al-Omari M, Maegel L, Muller M, Izykowski N, Hong J, et al. Anti-inflammatory and immunomodulatory properties of alpha-1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 2013;110(37):15067–12.
[10] McCarthy C, Dunlea DM, Saldova R, Henry M, Meleady P, McElvany OJ, et al. Glycosylation repurposes alpha-1 antitrypsin for resolution of community-acquired pneumonia. Am J Respir Crit Care Med 2018;197(10):1346–9.
[11] Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009;85(5):886–95.
[12] Stockley RA. Role of inflammation in respiratory tract infections. Am J Med 1995;99(6):85–135.
[13] Strnad P, McElvany NG, Lomas DA. Alpha-1-antitrypsin deficiency. N Engl J Med 2020;382(15):1443–51.
[14] McElvany OJ, Carroll TP, Franciosi AN, Sweeney J, Hobbs BD, Kowlessar V, et al. Consequences of abrupt cessation of alpha-1-antitrypsin replacement therapy. N Engl J Med 2020;382(15):1478–80.
[15] Jancauskaiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007;282(12):8573–82.
[16] Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, et al. The biological effects of double-dose alpha-1 antitrypsin augmentation therapy, a pilot clinical trial. Am J Respir Crit Care Med. 2019;200(3):318–26.
[17] McElvany OJ, Gunaratnam C, Reeves EP, McElvany NG. A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis. J Cyst Fibros 2019;18(2):203–11.
[18] McElvany OJ, Zaslona Z, Becker-Flegler P, Kalsonn-McDermott EM, Boland F, Gunaratnam C, et al. Specific inhibition of the NLRP3 inflammasome as an anti-inflammatory strategy in cystic fibrosis. Am J Respir Crit Care Med 2019.
[19] Forrest OA, Ingersoll SA, Preuninger MK, Laval J, Limoli DH, Brown MR, et al. Frontline science: pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis. J Leukoc Biol 2018;104(4):665–75.
[20] Carroll TP, Greene CM, Taggart CW, Bowie AG, O'Neill SJ, McElvany NG. Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells. J Immunol 2005;175(11):7594–601.
[21] Rose-John S, WINthrop K, Cabalrese L. The role of IL-6 in host defense against infections: immunobiology and clinical implications. Nat Rev Rheuma toll 2017;13(7):399–409.
[22] Kapnadak SG, Dimango E, Hadjiiladis D, Hempstead SE, Tallarico E, Pilewski JM, et al. Cystic fibrosis foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros 2020;19(3):344–54.
[23] Ramos KJ, Pilewski JM, Faro A, Marshall BC. Improved prognosis in cystic fibrosis: consideration for intensive care during the COVID-19 pandemic. Am J Respir Crit Care Med 2020;201(11):1434–5.
[24] Ramos KJ, Quon BS, Heltshle SL, Mayer-Hamblett N, Leake ED, Atkin ML, et al. Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States. Chest 2017;151(6):1320–8.
[25] Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmairer T, Bernhardt T, et al. Alpha-1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29(2):240–50.
[26] McElvany NG, Hubbard RC, Birrer P, Cherrnick MS, Caban DL, Frank MM, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337(8738):392–4.
[27] Gaggar A, Chen J, ChinellI F, Dorkin JM, Flume PA, Griffin R, et al. Inhaled al pha-1-protease inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros 2016;15(2):227–33.
[28] Harri L, Latzin P, Jordi P, Marcos V, Rudolph C, Woischinik M, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13(12):1423–30.